PMID- 28436601
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20181202
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 29
IP  - 5
DP  - 2017 May
TI  - Management of skin adverse events associated with immune checkpoint inhibitors in 
      patients with melanoma: A nursing perspective.
PG  - 294-303
LID - 10.1002/2327-6924.12458 [doi]
AB  - PURPOSE: Immune checkpoint inhibitors are associated with a unique immune-related 
      side effect profile that requires prompt recognition and management. Skin 
      toxicities are the most common, and often earliest occurring, drug-related 
      adverse events (AEs) of any grade observed upon treatment with these agents. The 
      purpose of this review is to provide practical guidance on the identification and 
      treatment of skin AEs associated with the immune checkpoint inhibitors 
      (ipilimumab, nivolumab, and pembrolizumab) from a nursing perspective, and 
      demonstrate hands-on application of the guidance using relevant patient case 
      studies. DATA SOURCES: Data for drug-related skin AEs were summarized from phase 
      3 nivolumab and nivolumab + ipilimumab trials and phase 2 and 3 pembrolizumab 
      trials. Patient case studies were provided by the lead (M.T.) and senior (J.N.C.) 
      authors. CONCLUSIONS: The recommendations presented here, based on accumulated 
      clinical trial and clinical practice experience are consistent with established 
      treatment guidelines and reach beyond established guidelines and recommendations 
      for the management of AEs associated with immune checkpoint inhibitors. 
      IMPLICATIONS FOR PRACTICE: The practical treatment guidance presented here may 
      help familiarize medical teams with the recognition and management of skin AEs 
      associated with these recently approved agents. The enclosed recommendations may 
      contribute to optimized treatment through awareness of typical time to onset and 
      clinical presentation, knowledge of management options, and appropriate 
      application of treatment.
CI  - (c)2017 American Association of Nurse Practitioners.
FAU - Thebeau, Melissa
AU  - Thebeau M
AD  - Moffitt Cancer Center, Tampa, Florida.
AD  - Bristol-Myers Squibb, Princeton, New Jersey.
FAU - Rubin, Krista
AU  - Rubin K
AD  - Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
FAU - Hofmann, Matthias
AU  - Hofmann M
AD  - Clinical Research, Department of Dermatology, Goethe University Frankfurt, 
      Frankfurt, Germany.
FAU - Grimm, Julia
AU  - Grimm J
AD  - Clinical Research, Uniklinikum Essen, Essen, Germany.
FAU - Weinstein, Alyona
AU  - Weinstein A
AD  - Memorial Sloan Kettering Cancer Center, New York, New York.
FAU - Choi, Jennifer N
AU  - Choi JN
AD  - Division of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center, 
      Northwestern University, Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20170424
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*etiology
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/therapeutic use
MH  - Ipilimumab
MH  - Male
MH  - Melanoma/*drug therapy
MH  - Middle Aged
MH  - Nivolumab
MH  - Skin Diseases/*etiology/therapy
MH  - Stevens-Johnson Syndrome/complications/etiology
OTO - NOTNLM
OT  - Cancer
OT  - advanced practice nurse
OT  - adverse events
OT  - immune checkpoint inhibitors
OT  - nurse
OT  - nurse practitioner
OT  - oncology
OT  - patient education
OT  - safety
OT  - skin
OT  - treatment guidelines
EDAT- 2017/04/25 06:00
MHDA- 2017/09/28 06:00
CRDT- 2017/04/25 06:00
PHST- 2016/10/17 00:00 [received]
PHST- 2017/02/21 00:00 [revised]
PHST- 2017/02/22 00:00 [accepted]
PHST- 2017/04/25 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2017/04/25 06:00 [entrez]
AID - 10.1002/2327-6924.12458 [doi]
PST - ppublish
SO  - J Am Assoc Nurse Pract. 2017 May;29(5):294-303. doi: 10.1002/2327-6924.12458. 
      Epub 2017 Apr 24.